Imperial Capital Remains Bullish as FireEye's (FEYE) Preliminary 4Q Results Were Consistent with Street

Streetinsider.com's Hot Lunchtime Reads 1/21: (JPM) (IIIN) (MNST) (FEYE) (ATVI)

The following is a list of notable articles to help get you through the lunch hour:JPMorgan tells investment bankers to take it easy on weekends ->... More

FireEye's (FEYE) Deal for iSight Slightly Rich, but Premium is Justified; FBN Trims PT to $22

FN Securities trims its price target on Outperform-rated FireEye (Nasdaq: FEYE) from $28 to $22 following preliminary Q4 results and acquisition of iSight Partners.

Analyst Shebly Seyrafi commented: FEYE announced that FQ4 revenue is expected to be $184-185M, at the low-end of the companys $182-190M guidance range, but NG billings is expected to be $256-257M, at the high-end of the companys $240-260M guidance. Moreover, the company... More

Notable Mergers and Acquisitions 1/21: (FEYE) (BC) (IMOS)

*** FireEye, Inc. (Nasdaq: FEYE) announced the acquisition of privately held iSIGHT Partners, one of the world's leading providers of cyber threat intelligence for global enterprises. The transaction closed on January 14, 2016.

With the acquisition, FireEye creates the world's most advanced and comprehensive private cyber threat intelligence operation. Customers of both companies will benefit from lower business risk through higher fidelity alerts, context to prioritize threats and the strategic insights to proactively prepare for threats that might target their industry or region. Existing iSIGHT customers will continue to have... More

Pre-Open Stock Movers 01/21: (ZFGN) (XLNX) (FEYE) Higher; (OGXI) (ALKS) (SLM) Lower (more...)

OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) 41.8% LOWER; announced that data from the Phase 2 Spruce trial evaluating the combination of apatorsen with carboplatin and pemetrexed in patients with untreated metastatic non-small cell lung cancer (NSCLC) did not reach the statistical significance required to demonstrate a progression-free survival (PFS) benefit. A potential PFS benefit was observed in patients with high baseline serum Hsp27 status when treated with apatorsen. The study is ongoing and overall survival results are expected in the second half of... More

Northland Capital Markets Starts FireEye, Inc (FEYE) at Outperform

Northland Capital Markets initiated coverage on FireEye, Inc (NASDAQ: FEYE) with an Outperform rating and a price target of $27.00.

For an analyst ratings summary and ratings history on FireEye, Inc click here. For more ratings news on FireEye, Inc click here.

Shares of FireEye, Inc closed at $14.87 yesterday.

FireEye (FEYE) Beats Low Expectations but Price Target Lowered at Deutsche Bank on Sector Re-Valuation

Deutsche Bank maintained a Hold rating on FireEye, Inc (NASDAQ: FEYE) but lowered its price target to $20.00 (from $30.00). Comments follow FireEye's positive pre-announcement. Analyst Karl Keirstead maintain a Hold rating due to FireEye's "balanced risk reward profile." The price target change relates to re-valuation across the software sector.

"FireEye (FEYE) pre-announced a modest 4Q15 revs beat and set preliminary 2016... More

FireEye (FEYE) Quarter Saved By the iSIGHT Acquisition - Piper Jaffray

Piper Jaffray analyst, Andrew Nowinski, took a critical view of FireEye, Inc (NASDAQ: FEYE) preannounced results and reduced his price target to $19 (from $27). FQ4(Dec) results are now expecting revenue to come in modestly below the mid-point of guidance. More importantly, management guided for organic billings growth of 20% in 2016, well below the Streets 28% estimate. However, the acquisition of iSIGHT will add ~$50M in billings to 2016, partially offsetting the guide down. The firm maintained a Neutral rating.

FireEye preannounced FQ4(Dec)... More

FireEye's (FEYE) Quarter Better Than Feared and Acquisition to Be Accretive in '16 - FBR

After the close, FireEye (NASDAQ: FEYE) announced the acquisition of iSIGHT Partners, a privately held threat intelligence player. The deal includes $200M of cash plus a potential $75M in cash/equity upon achievement of booking targets. The company has roughly $1.2B of cash in its treasure chest. The deal is expected to be modestly accretive to 2016... More

After-Hours Stock Movers 01/20: (ECYT) (XLNX) (FEYE) Higher; (OGXI) (SLM) (SRPT) Lower (more...)

OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) 41.8% LOWER; announced that data from the Phase 2 Spruce trial evaluating the combination of apatorsen with carboplatin and pemetrexed in patients with untreated metastatic non-small cell lung cancer (NSCLC) did not reach the statistical significance required to demonstrate a progression-free survival (PFS) benefit. A potential PFS benefit was observed in patients with high baseline serum Hsp27 status when treated with apatorsen. The study is ongoing and overall survival results are expected in the second half of 2016.

Endocyte, Inc. (NASDAQ:... More

Netgear, Inc. (NTGR) Adds FireEye's Summers as Director

NETGEAR®, Inc. (NASDAQ: NTGR) announced the appointment of Grady Summers to its board of directors. Mr. Summers brings extensive experience in technology trends, cybersecurity and cloud-based products and services in a variety of highly relevant global technology companies and industries. He fills a newly created seat on NETGEAR's board of directors and has been appointed as a member of the audit committee of the board as well. Mr. Summers... More

FireEye (FEYE) Prelim. Q4 Revenue Lighter than Expected; Moves to Acquire iSIGHT Partners

FireEye, Inc. (NASDAQ: FEYE), the leader in stopping today's advanced cyber attacks, today announced preliminary results for the fourth quarter of 2015.

Fourth quarter total billings, total revenue and non-GAAP loss per share are expected to be within previously issued guidance ranges. Total fourth quarter revenue is expected to be in the range of $184 million to $185 million and total fourth quarter billings are expected to be within the range of $256 million to $257 million. Further, the company also expects positive operating cash flow in the range of $7 to $9 million for the fourth quarter, resulting in... More

FireEye (FEYE) Acquires iSIGHT Partners for $200M

FireEye, Inc. (NASDAQ: FEYE) announced the acquisition of privately held iSIGHT Partners, one of the world's leading providers of cyber threat intelligence for global enterprises. The transaction closed on January 14, 2016.

With the acquisition, FireEye creates the world's most advanced and comprehensive private cyber threat intelligence operation. Customers of both companies will benefit from lower business risk through higher fidelity alerts, context to prioritize threats and the strategic insights to proactively prepare for threats that might target their industry or region. Existing iSIGHT customers will continue to have access to iSIGHT products. FireEye... More